FINWIRES · TerminalLIVE
FINWIRES

Globant Moves Closer to Becoming an AI-Native Tech Services Firm, Wedbush Says

By

Globant (GLOB) is still in the early stages of its turnaround as it continues to shift focus to AI-native services, with growth anticipated to return in Q2 and accelerate in H2, Wedbush said in a Friday note.

The company's Q1 total revenue beat expectations as more clients adopt its AI studios offering, with AI model independence and token sovereignty enabling flexibility for their internal use cases, Wedbush analysts said.

Meanwhile, Globant's AI Pods generated $32.8 million in revenue, an increase sequentially from $20.4 million, with 40% of its top 20 customers incorporating the offering, up from 30% in the prior quarter, according to the note.

The offering also expanded its sales pipeline to $352 million from $283 million in the previous quarter, positioning the company closer to becoming an AI-native tech services firm, the analysts said.

Globant needs to navigate an uncertain and complex macro environment that has made clients hesitant to commit large investments, the note said.

Wedbush maintained the company's stock rating at outperform and lowered the price target to $54 from $61.

Price: $38.89, Change: $+4.81, Percent Change: +14.11%

Related Articles

Australia

Solventum Seen Positioned for Meaningful Re-Rating Over Next 12 to 18 Months, Wedbush Says

Solventum (SOLV) shows a convergence of catalysts that should drive a meaningful valuation re-rating over the next 12 to 18 months, Wedbush Securities said in a Friday research note.The brokerage said its investment thesis on Solventum centers on the divestiture or spin-off of its non-core Dental Solutions and Health Info Systems segments, adding that these businesses are "strategically misaligned" with the core Medical Surgical segment.With activist investor Trian escalating its campaign for portfolio simplification, the company's "Transform for the Future" program targets EBIT margins between 23% and 25% by fiscal 2028 and includes the $4 billion Purification & Filtration divestiture. Wedbush said Solventum is seeing a convergence of catalysts that could unlock shareholder value.The investment firm added that Solventum's stock offers an attractive entry point at current levels for investors seeking exposure to a differentiated medical technology portfolio with identifiable near-term catalysts, activist accountability, and a clear path to pure-play re-rating.Wedbush initiated coverage with an outperform rating and a $94 price target.Price: $75.43, Change: $+1.01, Percent Change: +1.36%

$SOLV
Australia

BofA Adjusts Price Target on J.M. Smucker to $130 From $135

J.M. Smucker (SJM) has an average rating of overweight and mean price target of $117.87, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $99.53, Change: $+0.43, Percent Change: +0.43%

$SJM
Australia

Barclays Cuts DexCom Price Target to $64 From $67, Maintains Underweight Rating

DexCom (DXCM) has an average rating of overweight and mean price target of $83.08, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $62.64, Change: $+4.82, Percent Change: +8.34%

$DXCM